Antoxerene closes $1.5M for drug discovery in pathways of aging
Written by Welcome on August 23, 2017
LAFAYETTE, NY: Today, Antoxerene, a pharmaceutical company that develops small molecule drugs for pathways of aging, announced the closing of an oversubscribed $1.5M seed round. Michael Greve’s Kizoo Technology Capital, SENS Research Foundation, and private investors participated in the round.
Drug screening is commonly performed in the life sciences to identify leads for drug development. However, several biologic pathways of known importance to aging are unable to be screened effectively because proteins necessary for the screen cannot be manufactured at sufficient purity and scale.
“This is an exciting time to be working on a drug discovery initiative,” stated Kelsey Moody, CEO at Antoxerene. “We believe that our next generation screens will have higher predictive value than traditional approaches, and for some pathways, could give us first on-target therapeutic candidates.”
Under a co-development deal with Finger Lakes Bio, Antoxerene has used proprietary RecombiPure expression technology to develop screens for the p53/MDM2 pathway, a major oncology target, and the p53/FOXO4 pathway, a newly identified pathway involved in cellular aging, among others.
“High-throughput drug screens are an essential component of any medical research program,” stated Aubrey de Grey, CSO of SENS Research Foundation, which participated in the financing round. “A focus on small molecule screens will make pivotal contributions in the development of a broad range of therapies to repair the damage of aging – real rejuvenation biotechnology.”
Antoxerene is a pharmaceutical company that uses proprietary next generation screening technology to identify small molecule compounds to target pathways of aging. The company is headquartered in LaFayette, NY and is an affiliate of Ichor Therapeutics, Inc. For more information see: antoxerene.com
About Kizoo Technology Capital
Kizoo helps young start-up teams grow by providing mentoring, seed and early stage financing with a growing focus on Rejuvenation Biotech. It is part of Michael Greve´s Forever Healthy initiative to enable people to vastly extend their healthy lifespans and be part of the first generation to cure aging. For more information see: kizoo.com
This press release may contain certain forward-looking statements and information, as defined within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, and is subject to the Safe Harbor within such laws. This press release contains statements about expected future events that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Ichor Therapeutics, Inc. and Antoxerene, Inc. to be materially different from the statements made herein.